Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) is a Healthcare company (Biotechnology) with a market capitalization of $3.2B. The Maz Rating grades it against the other companies in its sector.
Acadia Pharmaceuticals Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $18.32, Acadia Pharmaceuticals Inc. trades at 8.5x trailing earnings, 2.6x sales and 2.3x book value, with an EV/EBITDA of 19.6. Over the last twelve months it generated about $1.2B of revenue and $372M of net income. It runs a gross margin of 90.5%, an operating margin of 10.2% and a net margin of 30.1%. It shows return on equity of 28.0%, return on invested capital of 8.3% and a free cash flow yield of 3.5%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 3.82. Over the past 52 weeks the share price ranged from $15.86 to $30.96, with a beta of 0.89.
Acadia Pharmaceuticals Inc. does not currently pay a dividend.
37 Wall Street analyst ratings cover the stock: 25 Buy, 11 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Acadia Pharmaceuticals Inc. (ACAD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 24.4% / 30% · Interest income / Revenue 2.46% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 24.4% / 33% · Receivables / Mkt Cap (36m) 4.46% / 49% · Interest income / Revenue 2.46% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 24.4% / 33.33% · Receivables / Mkt Cap (24m) 4.46% / 33.33% · Interest income / Revenue 2.46% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.35% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 53.7% / 33.33% · Receivables / Avg Assets (4Q) 9.56% / 33.33% · Interest income / Revenue 2.46% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 54.4% / 33.33% · (Cash+Recv) / Total Assets 64.4% / 33.33% · Interest income / Revenue 2.46% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Acadia Pharmaceuticals Inc. (ACAD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Acadia Pharmaceuticals Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.46% of each dividend: Acadia Pharmaceuticals Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.